703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)

首页> 外文期刊>European Journal of Cancer Supplements >703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)

【24h】

703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)

机译：703出版物卡培他滨联合奥沙利铂（XELOX），卡培他滨和伊立替康（XELIRI）在转移性结直肠癌（MCRC）一线治疗中的第二阶段多中心研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：636 POSTER卡培他滨（X）加奥沙利铂（XELOX）与输注5-FU / LV加奥沙利铂（FOLFOX-6）的III期临床研究在转移性结直肠癌患者（pts）的一线治疗中的初步安全性发现（ MCRC）
2. 3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) [J] . S.Cupini, S.Bursi, G.Masi, European Journal of Cancer Supplements . 2007,第4期

机译：3051年POSTER II期试验：卡培他滨和伊立替康，卡培他滨和奥沙利铂序贯化疗对转移性结直肠癌（MCRC）的老年弱势患者（pts）
3. 669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：669出版物卡培他滨和奥沙利铂（XELOX）作为晚期/转移性结直肠癌（MCRC）老年患者的一线治疗
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [O] . Daniela Bianconi, Merima Herac, Florian Posch, 2020

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列
6. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [O] . Daniela Bianconi, Merima Herac, Florian Posch, 2020

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果，翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab，然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列

703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)

著录项

相似文献

相关主题

期刊订阅